Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Case Reports
. 2024 Dec;74(12):704-707.
doi: 10.1111/pin.13494. Epub 2024 Nov 6.

SMARCB1-deficient renal medullary carcinoma with an EML4::ALK fusion gene in a Japanese woman

Megumi Nobuoka  1 , Tatsuya Mukawa  2 , Mai Iwaya  1 , Shohei Shigeto  1 , Tomonori Minagawa  2 , Takeshi Uehara  3 , Yoshiyuki Akiyama  2
Affiliations
Case Reports

SMARCB1-deficient renal medullary carcinoma with an EML4::ALK fusion gene in a Japanese woman

Megumi Nobuoka et al. Pathol Int. 2024 Dec.

Abstract

Renal medullary carcinoma is a rare, high-grade carcinoma arising in the renal medulla, which is usually associated with sickle cell trait, and there are very few documented cases in the Japanese population. We report a case of renal medullary carcinoma, immunohistochemically defined as SMARCB1 deficient, in a 67-year-old Japanese woman without a history of sickle cell trait. Somatic mutation of SMARCB1 and an EML4::ALK fusion gene were identified by comprehensive genomic profiling. Computed tomography revealed metastatic lesions in the retrocaval lymph nodes, liver, and bronchus. Six cycles of the dose-dense methotrexate, vinblastine, adriamycin, and cisplatin-combined chemotherapy were completed after an ultrasound-guided percutaneous biopsy of the renal tumor. After chemotherapy, the size of the original tumor in the right kidney had decreased in size, as well as the other metastatic lesions.

Keywords: EML4::ALK; EML4‐ALK; INI1; Japanese; SMARCB1; renal medullary carcinoma.

PubMed Disclaimer

References

REFERENCES

    1. WHO Classification of Tumours Editorial Board. WHO Classification of Urinary and Male Genital Tumours Fifth Edition. IARC: Lyon, 2022.
    1. Amin MB, Smith SC, Agaimy A, Argani P, Compérat EM, Delahunt B, et al. Collecting duct carcinoma versus renal medullary carcinoma: an appeal for nosologic and biological clarity. Am J Surg Pathol. 2014;38:871–874.
    1. Sirohi D, Smith SC, Ohe C, Colombo P, Divatia M, Dragoescu E, et al. Renal cell carcinoma, unclassified with medullary phenotype: poorly differentiated adenocarcinomas overlapping with renal medullary carcinoma. Hum Pathol. 2017;67:134–145.
    1. Iacovelli R, Modica D, Palazzo A, Trenta P, Piesco G, Cortesi E. Clinical outcome and prognostic factors in renal medullary carcinoma: a pooled analysis from 18 years of medical literature. Can Urol Assoc J. 2015;9:172.
    1. Motzer RJ, Jonasch E, Agarwal N, Alva A, Bagshaw H, Baine M, et al. NCCN Guidelines® Insights: Kidney Cancer, Version 2.2024: featured Updates to the NCCN Guidelines. J Natl Compr Cancer Netw. 2024;22:4–16.

Publication types

MeSH terms

LinkOut - more resources